Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion to continuous IRd after DRd response in newly diagnosed multiple myeloma
ChiCTR2400081601Phase 4Recruiting
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib, lenalidomide, dexamethasone and daratumumab in multiple myeloma (MM), sponsored by Beijing Jishuitan Hospital. Primary endpoints: M protein quantification, Bone marrow plasma cell percentage and 6 more. Started Mar 2024; status: recruiting.
02
Drugs
ixazomiblenalidomidedexamethasonedaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400081601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081601.